Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Operations: 2020-2025

Historic Cash from Operations for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$1.8 million.

  • Arcutis Biotherapeutics' Cash from Operations rose 94.94% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 80.58%. This contributed to the annual value of -$112.2 million for FY2024, which is 54.60% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Cash from Operations stood at -$1.8 million, which was down 641.36% from $324,000 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cash from Operations ranged from a high of $324,000 in Q2 2025 and a low of -$80.3 million during Q1 2023.
  • Over the past 3 years, Arcutis Biotherapeutics' median Cash from Operations value was -$34.7 million (recorded in 2024), while the average stood at -$35.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 119.91% in 2021, then skyrocketed by 100.72% in 2025.
  • Arcutis Biotherapeutics' Cash from Operations (Quarterly) stood at -$51.7 million in 2021, then crashed by 37.43% to -$71.1 million in 2022, then increased by 20.86% to -$56.2 million in 2023, then skyrocketed by 98.67% to -$748,000 in 2024, then surged by 94.94% to -$1.8 million in 2025.
  • Its Cash from Operations stands at -$1.8 million for Q3 2025, versus $324,000 for Q2 2025 and -$30.4 million for Q1 2025.